Retlirafusp alfa
Sponsors
Nanjing Tianyinshan Hospital, Tang-Du Hospital, The First Affiliated Hospital with Nanjing Medical University, Fudan University
Conditions
Esophageal Squamous Cell CarcinomaGastric AdenocarcinomaGastric Cancer/Gastroesophageal Junction AdenocarcinomaGastroesophageal Junction AdenocarcinomaHepatocellular Carcinoma(HCC)Intrahepatic Cholangiocarcinoma (Icc)Neoadjuvant TherapyPancreatic Cancer
Phase 2
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
Not yet recruitingNCT07618910
Start: 2026-05-30End: 2028-05-30Target: 33Updated: 2026-06-01
Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruitingNCT07709767
Start: 2026-08-30End: 2032-08-30Target: 21Updated: 2026-07-17
Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer
Not yet recruitingNCT07773363
Start: 2026-08-30End: 2028-12-30Target: 37Updated: 2026-08-19
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
RecruitingNCT07847710
Start: 2026-09-30End: 2029-03-01Target: 81Updated: 2026-10-28
Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC
Not yet recruitingNCT07874425
Start: 2026-10-01End: 2028-12-01Target: 55Updated: 2026-10-14